Skip to main content

Table 1 Clinical and demographic data of study participants

From: Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics

    Training Sample Validation Sample
  Healthy controls ALS patients surviving   ALS patients surviving  
   p-value* < 18 months > 18 months p-value < 18 months > 18 months p-value
n 69   24 24   6 6  
Gender (male/ female) 34/35 P = 0.22 17/7 13/11 P = .37 3/3 2/4 P = 1
Handedness (right/left) 64/5 P = .55 23/1 20/4 P = .35 5/1 5/1 P = 1
Age, years (means, SD**) 59.97 (9.9) P = .17 63.18 (8) 61.76 (10.73) P = .60 63.96 (8.03) 55.09 (8.82) P = .09
Site of onset (bulbar/spinal)    8/16 10/14 P = .76 3/3 2/4 P = 1
Diagnostic delay, years (mean, SD)    1.2 (0.81) 1.05 (0.75) P = .51 1.28 (1.1) 0.88 (0.3) P = .43
Disease duration from symptom onset until scan, years (mean, SD)    2.17 (1.01) 2.32 (1.34) P = .67 1.94 (1.44) 1.85 (0.54) P = .89
ALSFRS-r (mean, SD)    34.48 (6.84) 37.38 (6.21) P = .12 34.5 (8.34) 39.17 (4.17) P = .25
King’s College Staging (1/ 2/ 3/ 4/ unavailable)    4/5/3/7/5 4/9/5/4/2   0/1/2/2/1 2/2/1/1/0  
MITOS Staging (0 /1/ 2/ 3/ unavailable)    10/8/1/0/5 19/2/0/1/2   3/1/1/0/1 6/0/0/0/0  
Survival from scan, years (mean, SD)    0.94 (0.32) 2.26 (1.11) P < .01 0.92 (0.26) 2.62 (1.32)** P < .05
  1. *healthy controls were compared to the training sample of 48 patients. **SD standard deviation